Patents Assigned to Immunomic Therapeutics, Inc.
  • Publication number: 20240108703
    Abstract: The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and/or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.
    Type: Application
    Filed: October 17, 2020
    Publication date: April 4, 2024
    Applicant: Immunomic Therapeutics, Inc.
    Inventor: Teri Heiland
  • Patent number: 11826423
    Abstract: The present invention provides DNA vaccines for the treatment or prevention of an allergic response. The vaccines comprise the coding sequence for Allergen X or fragments thereof fused in-frame with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: November 28, 2023
    Assignee: Immunomic Therapeutics, Inc.
    Inventor: Teri Heiland
  • Publication number: 20220081474
    Abstract: Nucleic acids (also referred to herein as “constructs”) that encode allergenic proteins, allergenic polypeptides, and allergenic peptides are provided. The nucleic acids are designed for delivery to immune cells and production of allergenic proteins, polypeptides, and peptides within those cells. The encoded proteins, polypeptides, and peptides have targeting sequences for targeting of the proteins to the MHC-II compartment for processing and display of one or more epitopes, resulting in an immune response to the epitope(s). In general, the nucleic acids comprise the following domains, which correlate to the respective domains of the encoded protein: a signal sequence domain; an intra-organelle stabilizing domain; an allergen domain; a transmembrane domain; and a cytoplasmic lysosome/endosome targeting domain.
    Type: Application
    Filed: September 22, 2020
    Publication date: March 17, 2022
    Applicant: Immunomic Therapeutics, Inc
    Inventors: William Hearl, Teri Heiland
  • Patent number: 11203629
    Abstract: The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular, allergies, infectious disease, diabetes, hyperproliferative disorders and/or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.
    Type: Grant
    Filed: April 22, 2018
    Date of Patent: December 21, 2021
    Assignee: Immunomic Therapeutics, Inc.
    Inventor: Teri Heiland
  • Publication number: 20210261647
    Abstract: The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver allergens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular allergic reactions and/or allergies. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs.
    Type: Application
    Filed: May 14, 2019
    Publication date: August 26, 2021
    Applicant: Immunomic Therapeutics, Inc
    Inventor: Teri HEILAND
  • Publication number: 20200377570
    Abstract: The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular, allergies, infectious disease, diabetes, hyperproliferative disorders and/or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.
    Type: Application
    Filed: April 22, 2018
    Publication date: December 3, 2020
    Applicant: Immunomic Therapeutics, Inc
    Inventor: Teri Heiland
  • Publication number: 20200087365
    Abstract: The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and/or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 19, 2020
    Applicant: Immunomic Therapeutics, Inc
    Inventor: Teri Heiland
  • Publication number: 20190351050
    Abstract: The present invention provides DNA vaccines for the treatment or prevention of an allergic response. The vaccines comprise the coding sequence for Allergen X or fragments thereof fused in-frame with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.
    Type: Application
    Filed: November 15, 2017
    Publication date: November 21, 2019
    Applicant: Immunomic Therapeutics, Inc
    Inventor: Teri Heiland
  • Publication number: 20190298821
    Abstract: Provided herein are DNA vaccines for the treatment of peanut allergies. The vaccines comprise the coding sequence for one or more peanut allergenic epitopes fused in-frame with the luminal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines can be multivalent molecules and/or can be provided as part of a multivalent vaccine comprising two or more DNA constructs.
    Type: Application
    Filed: March 17, 2019
    Publication date: October 3, 2019
    Applicant: Immunomic Therapeutics, Inc
    Inventors: William Hearl, Teri Heiland
  • Patent number: 10072053
    Abstract: The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: September 11, 2018
    Assignee: Immunomic Therapeutics, Inc.
    Inventors: William Hearl, Teri Heiland
  • Publication number: 20180009857
    Abstract: The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.
    Type: Application
    Filed: July 31, 2017
    Publication date: January 11, 2018
    Applicant: Immunomic Therapeutics, Inc
    Inventors: William Hearl, Teri Heiland
  • Patent number: 9744230
    Abstract: The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: August 29, 2017
    Assignee: Immunomic Therapeutics, Inc.
    Inventors: William Hearl, Teri Heiland
  • Publication number: 20160271245
    Abstract: The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 22, 2016
    Applicant: Immunomic Therapeutics, Inc.
    Inventors: William Hearl, Teri Heiland
  • Publication number: 20160185831
    Abstract: The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.
    Type: Application
    Filed: June 15, 2012
    Publication date: June 30, 2016
    Applicant: Immunomic Therapeutics, Inc.
    Inventors: William Hearl, Teri Heiland